



Press release from Emotra AB (publ)
Göteborg, May 19, 2017

EMOTRA AB (publ): EGM bulletin

Today, on May 19, 2017, Emotra AB (publ) held an extraordinary general meeting of shareholders. The resolution, summarised below, was adopted with the necessary majority.

Resolution on granting the Board authority to decide on a new share issue with right of priority

The EGM resolved to authorise the Board to issue new shares, on one or more occasions up until the next AGM, without deviation from the shareholders' preferential rights.

The number of shares issued under the authorisation shall correspond to a maximum amount of 20 MSEK (SEK 20,000,000 in total issue proceeds).

The shares will be issued at a market-equivalent price, minus a market-rate issue rebate, when appropriate, and payment can, in addition to cash, be made in kind or as otherwise conditioned.

The goal of any new share issue that is decided based on the granted authority shall be to reinforce the Company's working capital to finance the market launch of the Company's method EDOR®.

The meeting also resolved to authorise the Board, or a person appointed by the Board, to make any minor adjustments to the EGM resolution that may prove necessary when registering the decision.

Göteborg, May, 2017
Emotra AB (publ)
THE BOARD OF DIRECTORS

For further information about the Company, please contact:

Claes Holmberg, CEO
Telephone: +46 708 25 45 47
E-mail: claes@emotra.se

***Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.*

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden
Tel: +46 708 25 45 47, www.emotra.se